![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Reduces Risk of Heart](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Reduces Risk of Heart
USD24.71
USD67.71
Pay in 4 interest-free payments of $6.18 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Reduces Risk of Heart](https://cdn.sanity.io/images/0vv8moc6/patientcare/316a4db2c4f4ca4cd65d61f557880d0739bd6544-630x445.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Reduces Risk of Heart](https://www.acc.org/-/media/Non-Clinical/Images/Latest-in-Cardiology/Journal-Scans/2026/Borlaug-Central-Illustration.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Reduces Risk of Heart](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/dt_241105_tirzepatide_800x450.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Reduces Risk of Heart](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=4268034086816797&get_thumbnail=1)
-1.jpg&w=3840&q=75)
